Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now
Key Stock Data
The current last sale of $8 is 113.90% Higher than the 52 week low.
|Intraday||Last 52 Weeks|
|High:||$ 8.15||$ 38.8239|
|Low:||$ 7.74||$ 3.74|
Company Description (as filed with the SEC)
We are a late-stage biopharmaceutical company focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with various conditions such as prurigo nodularis, psoriasis and chronic pruritus of unknown origin, or CPUO. We believe that serlopitant, a highly selective small molecule inhibitor of the neurokinin 1 receptor, or NK1-R, given as a once-daily, oral tablet, has the potential to significantly alleviate pruritus. More than 80 million patients in the United States are affected by chronic pruritus associated with various conditions. Chronic pruritus is defined as pruritus lasting longer than six weeks. Pruritus is the primary complaint among patients with prurigo nodularis, psoriasis, and CPUO, often significantly impacting their quality of life. Current therapies, however, do not adequately control pruritus in many of these patients. ... More ...
Nasdaq Official Price
Mar. 18, 2019
Mar. 18, 2019